deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT01442792

Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention (X-PLORER)

Prospective, Multi-center, Randomized, Heparin-controlled Dose-finding Trial to Evaluate the Efficacy and Safety of Rivaroxaban, a Direct Factor Xa Inhibitor, on the Background of Standard Dual Antiplatelet Therapy to Support Elective Percutaneous Coronary Intervention

Sponsor: Bayer

Conditions Cardiovascular Disease Coronary Artery Disease
Interventions Rivaroxaban (Xarelto, BAY59-7939) Rivaroxaban (Xarelto, BAY59-7939) and UFH UFH
Updated 9 times since 2017 Last updated: Jun 20, 2022 Started: Oct 12, 2011 Primary completion: Jan 29, 2013 Completion: Mar 4, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01442792, this PHASE2 trial focuses on Cardiovascular Disease and Coronary Artery Disease and remains completed. Sponsored by Bayer, it has been updated 9 times since 2011, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshotCompleted~Apr 2019 – ~Jan 2021 · 21 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2022 · 18 months · monthly snapshotCompleted~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 11 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jul 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Jul 2022 [monthly]

    Completed PHASE2

▶ Show 4 earlier versions

  1. Apr 2019 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jun 2018 — Apr 2019 [monthly]

    Completed PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • Janssen Research & Development, LLC
Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations